Drug intelligence / Profile preview

caudatin

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Caudatin is a C21 steroidal glycoside isolated from plants of the genus Cynanchum. It has been used in traditional medicine and is known for its anticancer properties. Caudatin induces apoptosis in cancer cells by modulating the expression of pro-apoptotic and anti-apoptotic proteins, and it inhibits cell proliferation and migration. It interacts with multiple molecular targets, including uPA, MMP9, and JAK2. Caudatin also inhibits tumor growth in vivo by reducing tumor size and weight.

Other names: Caudatin-RM(3β,12β,14β,17α)-12-[[(2E)-3,4-Dimethyl-1-oxo-2-pentenyl]oxy]-3,8,14,17-tetrahydroxypregn-5-en-20-one

Targets

BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)TNFAIP1 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 3)JAK2 (Janus kinase 2)PLAU (uPA)CYCS (Cytochrome c)NF-κBMMP9 (Matrix metalloproteinase-9)

Beyond the preview

Go deeper on caudatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on caudatin.

Explore the full profile